Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Heterozygous glucokinase (GCK) mutations cause mild, fasting hyperglycaemia from birth. Although patients are usually asymptomatic and have glycaemia within target ranges, some are put on pharmacological treatment. We aimed to investigate how many patients are on pharmacological treatment and the impact of treatment on glycaemic control. METHODS: Treatment details were ascertained for 799 patients with heterozygous GCK mutations. In a separate, longitudinal study, HbA1c was obtained for 16 consecutive patients receiving insulin (n = 10) or oral hypoglycaemic agents (OHAs) (n = 6) whilst on treatment, and again having discontinued treatment following a genetic diagnosis of GCK-MODY. For comparison, HbA1c before and after genetic testing was studied in a control group (n = 18) not receiving pharmacological therapy. RESULTS: At referral for genetic testing, 168/799 (21%) of patients were on pharmacological treatment (13.5% OHAs, 7.5% insulin). There was no difference in the HbA1c of these patients compared with those receiving no treatment(median [IQR]: 48 [43, 51] vs 46 [43, 50] mmol/mol, respectively; 6.5% [6.1%, 6.8%] vs 6.4% [6.1%, 6.7%]; p = 0.11). Following discontinuation of pharmacological treatment in 16 patients, HbA1c did not change. The mean change in HbA1c was -0.68 mmol/mol (95% CI: -2.97, 1.61) (-0.06% [95% CI: -0.27, 0.15]). CONCLUSIONS/INTERPRETATION: Prior to a genetic diagnosis, 21% of patients were on pharmacological treatment. HbA1c was no higher than in untreated patients and did not change when therapy was discontinued, suggesting no impact on glycaemia. The lack of response to pharmacological therapy is likely to reflect the regulated hyperglycaemia seen in these patients owing to their glucose sensing defect and is an example of pharmacogenetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 3×
“Patients with hepatocyte nuclear factor-1α/-4α (HNF1A/ HNF4A)-MODY are sensitive to low doses of sulfonylureas [9] and those with activating KCNJ11/ABCC8 mutations causing neonatal diabetes are best treated with high-dose sulfonylureas [8].”
BackgroundMethodSelf-citationGenetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14571-0 · Cited by 607
Self-citation
Cited by
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Steele, A. M., Shields, B. M., Wensley, K. J., Colclough, K., Ellard, S., & Hattersley, A. T. (2014) · JAMA · doi:10.1001/jama.2013.283980 · Cited by 381
Self-citationHattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“is rarely associated with chronic microvascular or macrovascular complications of diabetes (118, 119) and patients do not generally require any treatment (120) except in the setting of pregnancy where an affected mother has an unaffected fetus and there is in utero evidence of macrosomia (121) .”
Self-citationPrecision diabetes: learning from monogenic diabetes
Hattersley, A. T., & Patel, K. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4226-2 · Cited by 306
Self-citationChakera, A. J., Steele, A. M., Gloyn, A. L., Shepherd, M. H., Shields, B., Ellard, S., & Hattersley, A. T. (2015) · Diabetes Care · doi:10.2337/dc14-2769 · Cited by 289
Self-citationGreeley, S. A. W., Polak, M., Njølstad, P. R., Barbetti, F., Williams, R., Castano, L., Raile, K., Chi, D. V., Habeb, A., Hattersley, A. T., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13426 · Cited by 211
Self-citationChung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Self-citationMaturity-onset diabetes of the young (MODY): an update
Anık, A., Çatlı, G., Abacı, A., & Böber, E. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0384 · Cited by 198
The diagnosis and management of monogenic diabetes in children and adolescents
Rubio-Cabezas, O., Hattersley, A. T., Njølstad, P. R., Mlynarski, W., Ellard, S., White, N., Chi, D. V., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12192 · Cited by 196
Self-citationApproach to the patient with mody-monogenic diabetes
Broome, D. T., Pantalone, K. M., Kashyap, S. R., & Philipson, L. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa710 · Cited by 159
Shields, B. M., Shepherd, M., Hudson, M., McDonald, T. J., Colclough, K., Peters, J., Knight, B., Hyde, C., Ellard, S., Pearson, E. R., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0224 · Cited by 151
Self-citationRiddle, M. C., Philipson, L. H., Rich, S. S., Carlsson, A., Franks, P. W., Greeley, S. A. W., Nolan, J. J., Pearson, E. R., Zeitler, P. S., & Hattersley, A. T. (2020) · Diabetes Care · doi:10.2337/dci20-0065 · Cited by 117
Self-citationCarmody, D., Naylor, R. N., Bell, C. D., Berry, S., Montgomery, J. T., Tadie, E. C., Hwang, J. L., Greeley, S. A. W., & Philipson, L. H. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0859-8 · Cited by 84
“The following criteria were used to select probands for research genetic testing for GCK-MODY: chronic mild fasting hyperglycemia (100–140 mg/dl, 5.55–7.75 mmol/l) and HbA1c 5.6–7.8 % (38–62 mmol/mol) plus a linear three-generation family history of hyper- glycemia or diabetes mellitus or BMI less than 30 kg/m2 in adu…”
BackgroundMethodInfluentialSearching for maturity-onset diabetes of the young (MODY): when and what for?
Timsit, J., Saint-Martin, C., Dubois-Laforgue, D., & Bellanné-Chantelot, C. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.12.005 · Cited by 55
A comprehensive map of human glucokinase variant activity
Gersing, S., Cagiada, M., Gebbia, M., Gjesing, A. P., Coté, A. G., Seesankar, G., Li, R., Tabet, D., Weile, J., Stein, A., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02935-8 · Cited by 55
Schiabor Barrett, K. M., Telis, N., McEwen, L. M., Burrows, E. K., Khuder, B., Judge, D. P., Pawloski, P. A., Grzymski, J. J., Washington, N. L., Bolze, A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00663-z · Cited by 8
Metadata
- Authors
- Stride, A., Shields, B., Gill-Carey, O., Chakera, A. J., Colclough, K., Ellard, S., & Hattersley, A. T.
- Venue
- Diabetologia
- Published
- 2013-10-04
- Volume
- 57
- Issue
- 1
- Pages
- 54-56
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2097748435
- Cited by
- 212
- References
- 2
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.